Sarasota, Florida – November 20, 2018 Kali, Inc. (USOTC: KALY) today announced publishing a new website and hosting an online shareholder presentation from the new website. The presentation details the company’s new business plan following the acquisition of a patented botanical extraction process to include the acquisition of ongoing pharmaceutical and concentrate research being conducted in conjunction with the patented extraction process. The presentation can be found on the company’s new website at www.kali-extracts.com. The narrative from the presentation is included in its entirety below.
Last week, Kali Inc announced the acquisition of NCM Biotech which is the developer and owner of a patented botanical extraction process - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING ...” NCM Biotech’s current research and ongoing pharmaceutical developments come with the acquisition.
NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs.
With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali will now concentrate on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali will also concentrate on the development of health and wellness therapies. The specific pharmaceuticals market Kali-Extracts is targeting is forecasted to reach $50 billion in sales by 2029. The specific wellness market Kali-Extracts is targeting is forecasted to reach $8.5 billion in annual sales by 2022.
Prior to the acquisition by Kali, NCM Biotech was engaged with a number of different universities on a number of separate research initiatives. As an example, and as a preview of an upcoming announcement, NCM has been involved in an ongoing study with a university in Kentucky on the use of therapy derived from Kali’s patented extraction process for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A paper on the results of the study using Kali’s patented extraction process is anticipated to be published soon.
Kali issued a $1.5 million note in exchange for 100% of the issued and outstanding shares of NCM Biotech. In a related transaction, the majority shareholder voting control affected through preferred shares, was assigned to the NCM Biotech seller. No common shares of Kali were issued in the acquisition of NCM Biotech and Kali has no intention of executing either a reverse or forward split of Kali shares in conjunction with the acquisition of NCM Biotech. Kali financial reports are being updated as this presentation is drafted, and the filing of the necessary financial statements required to bring the company current are anticipated to be completed imminently.
On the company website, shareholders will note a new address and telephone number. A new email address will be coming soon as well. The physical address and new telephone number have been secured, but the transition process is still underway. Shareholders can reach the company electronically form the contact page on the new company website. The old contact information will remain live for a short period of time.
Kali recently announced is partnership in a Joint Venture, to combine its resources and expertise with those of Puration, Inc. (PURA) and Nouveau Life Pharmaceuticals, Inc. (NOUV) to together attract partnerships with major pharmaceutical firms for pharmaceutical developments. With both Puration and Nouveau operations in the North Texas region, Kali will also relocate its primary operations to the North Texas region.
The presentation today is a glimpse of what the NCM Biotech acquisition brings. Stay tuned and check back frequently for further details and future updates.